(NASDAQ:IMMX) IMMIX BIOPHARM INC. share are rallying this morning in pre-market up to $2.66 a share.  Shares are up more than 43% on more than 21,000 trades one hour before the open.

ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study

• One cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug)
• In a connective tissue cancer Soft Tissue Sarcoma (STS) mice study, IMX-110 was compared against approved drugs
• IMX-110 is in clinical development for STS, a $3 billion market expected to grow to $6.5 billion by 2030

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/38fdaa24-38ff-482c-8b72-63baa730a3a2

https://www.globenewswire.com/news-release/2022/05/20/2447697/0/en/ImmixBio-IMX-110-Demonstrated-Improved-Survival-Over-U-S-Food-and-Drug-Administration-Approved-Drug-Trabectedin-sold-as-YONDELIS-by-Janssen-a-Johnson-Johnson-Company-in-Connective-.html